Authors' recommendations: Type 1 diabetes occurs when the person's own immune system attacks the pancreas and destroys the cells that produce a hormone called insulin, which is needed to regulate the body's sugar levels. Without insulin, there is too much sugar in the blood. This can cause damage to the eyes, nerves, kidneys and other tissues, and can increase the chances of heart attacks and strokes. Empagliflozin is a drug currently used to treat type 2 diabetes. It is given as a tablet that is taken once daily. Empagliflozin is currently being studied to see if it would also work in patients with type 1 diabetes, to be taken alongside the insulin injections that patients already take. If licensed in the UK, empagliflozin will offer type 1 diabetes patients an additional treatment option alongside insulin to maintain stable sugar levels.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/empagliflozin-jardiance-for-type-1-diabetes-adjunctive-therapy/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)